Founded in 2014, Cann Group Limited develops medicinal cannabis products to improve the quality of life of Australian patients. They aim to provide access to a range of quality medicinal cannabis products for patients both local and global.
They were the first Australian company to receive licensing and permit for the cultivation of medicinal cannabis from the Australian Federal Government, and they are a proud member of the Medicinal Cannabis Industry Association.
Cann Group Limited works with organizations in Australia and overseas to acquire elite genetic material for the local development of specific genetic strains of cannabis using advanced breeding programs. These extracts are provided to researchers and prescribing clinicians for investigation, understanding and optimization of the therapeutic effectiveness of medicinal cannabis for specific medical conditions.
Cann Group Limited’s relationships with Agriculture Victoria, La Trobe University, CSIRO and pioneering research institutions such as the Olivia Newton-John Cancer Research Institute and Pancare allow them to partner with clinical researchers to tailor cannabis strains through their genetic profiling and breeding programs. Their board of directors and management are experienced in the agriculture, agronomic and health research sectors and in developing and commercialising agricultural technology.
Cann Group Limited medicinal cannabis products can be legally prescribed to eligible patients for treatment of medical conditions, including:
- Palliative care
- Chronic non-cancer pain
- Nausea and vomiting
- Multiple sclerosis
- Paediatric and young adult epilepsy
Australian patients can access medicinal cannabis through the TGA’s Special Access Scheme and Authorised Prescriber scheme or through participation in a clinical trial. Once medicinal cannabis products have been registered on the Australian Register of Therapeutic Goods, any doctor will be able to prescribe them for patient treatment.
